The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Overview of attention for article published in Journal for Immunotherapy of Cancer, August 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

So far, Altmetric has seen 27 X posts from 12 X users, with an upper bound of 45,120 followers.

MEK 抑制剂 selumetinib 通过重新编程肿瘤免疫微环境来补充 CTLA-4 阻断 Edmund Poon 1 , 斯蒂芬妮·穆林 https://t.co/O9EmyR8HRU

Claudia Manriquez Roman, an #ECR from @MayoClinic, shows at #SITC22 that #MEKinhibitors may sensitize #ThyroidCancer to #CAR #TCELL therapy. Check out this #JITC article to read more about the impacts of MEK inhibitors with #IO on the #TME: https://t.co/X1

#JITC: The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment https://t.co/i8OPvg7AjR https://t.co/b5rzINblyF

RT @sitcancer: #JITC: The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment https://…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 23 additional X posts.